Risk factors associated with drug therapy among elderly people with Alzheimer’s disease
a cross-sectional study
Palavras-chave:
Dementia, Patient safety, PolypharmacyResumo
BACKGROUND: Improving knowledge and establishing strategies and policies for better patient safety are worldwide priorities. OBJECTIVE: To evaluate drug safety among elderly people with Alzheimer’s disease (AD). DESIGN AND SETTING: Cross-sectional study among elderly people within the National AD Assistance Protocol (PCDTDA/MS) who were living in the municipality of Araraquara, Brazil, in 2017. METHODS: Through interviews conducted with relatives/caregivers of elderly people with diagnoses of AD, the following variables were evaluated: comorbidities, drug therapy used, use of potentially inappropriate medications for the elderly (PIMs), presence of potentially inappropriate interactions (PIIs) and medication regimen complexity index. Factors associated with AD severity were also evaluated. Multivariate and simple logistic regressions were applied. RESULTS: 143 elderly people enrolled in PCDTDA/MS were analyzed. The majority were women (67.1%); assisted only through the public healthcare system (75.5%); polymedicated (57.4%); using at least one PIM (63.6%); presenting at least one PII (63.6%); and under drug therapy of low to medium complexity (92.2%). No semi-annual monitoring of the effectiveness of PCDTDA/MS drugs was identified. The proportion usingAD drug therapy at daily doses differing from those recommended by the World Health Organization was 75.6%. However, these doses were not associated with drug risk. CONCLUSION: The data from this study raise the hypothesis that use of polypharmacy might show a correlation with severity of AD. The drug safety risk may be associated with comorbidities of the metabolic syndrome, anxiety and off-label use of PIMs, such as risperidone and quetiapine, and benzodiazepines (i.e. clonazepam and flunitrazepam).
Downloads
Referências
Shade MY, Berger AM, Chaperon C, et al. Factors Associated With Potentially Inappropriate Medication Use in Rural, Community-welling Older Adults. J Gerontol Nurs. 2017;43(9):21-30. PMID: 28399319; doi: 10.3928/00989134-20170406-01.
Alves-Conceição V, Rocha KSS, Silva FVN, et al. Medication Regimen Complexity Measured by MRCI: A Systematic Review to Identify Health Outcomes. Ann Pharmacother. 2018;52(11):1117-34. PMID: 29756471; doi: 10.1177/1060028018773691.
Varallo FR, Costa MA, Mastroianni P de C. Potenciais interações medicamentosas responsáveis por internações hospitalares. Rev Ciencias Farm Basica e Apl. 2013;34(1):79-85. Available from: Available from: http://hdl.handle.net/11449/107431 Accessed in 2019 (Oct 24).
Fried TR, O’Leary J, Towle V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62(12):2261-72. PMID: 25516023; doi: 10.1111/jgs.13153.
Chen YC, Fan JS, Chen MH, et al. Risk factors associated with adverse drug events among older adults in emergency department. Eur J Intern Med. 2014;25(1):49-55. PMID: 24200546; doi: 10.1016/j.ejim.2013.10.006.
Salvi F, Marchetti A, D’Angelo F, et al. Adverse drug events as a cause of hospitalization in older adults. Drug Saf. 2012;35(Suppl 1):29-45. PMID: 23446784; doi: 10.1007/BF03319101.
Varallo FR, Capucho HC, Silva Planeta CD, Carvalho Mastroianni PD. Possible adverse drug events leading to hospital admission in a Brazilian teaching hospital. Clinics (Sao Paulo). 2014;69(3):163-7. PMID: 24626940; doi: 10.6061/clinics/2014(03)03.
O’Mahony D, Gallagher PF. Inappropriate prescribing in the older population: need for new criteria. Age Ageing. 2008;37(2):138-41. PMID: 18349010; doi: 10.1093/ageing/afm189.
Dormann H, Sonst A, Müller F, et al. Adverse drug events in older patients admitted as an emergency: the role of potentially inappropriate medication in elderly people (PRISCUS). Dtsch Arztebl Int. 2013;110(13):213-9. PMID: 23596501; doi: 10.3238/arztebl.2013.0213.
Albert SM, Colombi A, Hanlon J. Potentially inappropriate medications and risk of hospitalization in retirees: analysis of a US retiree health claims database. Drugs Aging. 2010;27(5):407-15. PMID: 20450238; doi: 10.2165/11315990-000000000-00000.
Varallo FR, Oliveira FM, Mastroianni PC. Safety assessment of essential medicines for elderly people: a bibliographic survey. Brazilian J Pharm Sci. 2014;50(2):269-84. doi: 10.1590/S1984-82502014000200006.
World Health Organization (WHO). Dementia [Internet]. WHO; 2019. Available from: Available from: http://www.who.int/mediacentre/factsheets/fs362/en/ Accessed in 2019 (Oct 24).
Burns A, Iliffe S. Alzheimer’s disease. BMJ. 2009;338:b158. PMID: 19196745; doi: 10.1136/bmj.b158.
Bosboom PR, Alfonso H, Almeida OP, Beer C. Use of Potentially Harmful Medications and Health-Related Quality of Life among People with Dementia Living in Residential Aged Care Facilities. Dement Geriatr Cogn Dis Extra. 2012;2(1):361-71. PMID: 23277778; doi: 10.1159/000342172.
Lau DT, Mercaldo ND, Shega JW, Rademaker A, Weintraub S. Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia. Am J Alzheimers Dis Other Demen. 2011;26(8):606-15. PMID: 22207646; doi: 10.1177/1533317511432734.
Montastruc F, Gardette V, Cantet C, et al. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs! Eur J Clin Pharmacol. 2013;69(8):1589-97. PMID: 23588564; doi: 10.1007/s00228-013-1506-8.
Renom-Guiteras A, Thürmann PA, Miralles R, et al. Potentially inappropriate medication among people with dementia in eight European countries. Age Ageing. 2018;47(1):68-74. PMID: 28985257; doi: 10.1093/ageing/afx147.
von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-9. PMID: 18313558; doi: 10.1016/j.jclinepi.2007.11.008.
Costa AF, Chaves MLF, Picon PD, et al. Protocolo Clínico e Diretrizes Terapêuticas - Doença de Alzheimer. Portaria Conjunta no 13, de 28 de novembro de 2017 [Internet]. 2017;147-67.
Frota NAF, Nitrini R, Damasceno BP, et al. Criteria for the diagnosis of Alzheimer’s disease: Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dement Neuropsychol. 2011;5(3):146-52. PMID: 29213739; doi: 10.1590/S1980-57642011DN05030002.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98. PMID: 1202204; doi: 10.1016/0022-3956(75)90026-6.
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72. PMID: 7104545; doi: 10.1192/bjp.140.6.566.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, valuation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. PMID: 12485966.
Melchiors AC, Correr CJ, Fernández-Llimos F. Translation and validation into Portuguese language of the medication regimen complexity index. Arq Bras Cardiol. 2007;89(4):210-8. PMID: 17992376; doi: 10.1590/s0066-782x2007001600001.
Paquin AM, Zimmerman KM, Kostas TR, et al. Complexity perplexity: a systematic review to describe the measurement of medication regimen complexity. Expert Opin Drug Saf. 2013;12(6):829-40. PMID: 23984969; doi: 10.1517/14740338.2013.823944.
Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716-24. PMID: 14662625; doi: 10.1001/archinte.163.22.2716.
American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227-46. PMID: 26446832; doi: 10.1111/jgs.13702.
O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-8. PMID: 25324330; doi: 10.1093/ageing/afu145.
Laroche ML, Charmes JP, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725-31. PMID: 17554532; doi: 10.1007/s00228-007-0324-2.
McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385-91. PMID: 9033421.
Straand, J, Rokstad KS . Elderly patients in general practice: diagnoses, drugs and inappropriate prescriptions. A report from the Møre & Romsdal Prescription Study. Fam Pract. 1999;16(4):380-8. PMID: 10493709; doi: 10.1093/fampra/16.4.380.
Bellostas-Muñoz L, Díez-Manglano J. Complexity of the medication regimen for polypathological patients. Rev Clin Esp. 2018;218(7):342-50. PMID: 29784546; doi: 10.1016/j.rce.2018.04.009.
Leelakanok N, D’Cunha RR. Association between polypharmacy and dementia - A systematic review and metaanalysis. Aging Ment Health. 2019;23(8):932-41. PMID: 29746153; doi: 10.1080/13607863.2018.1468411.
Park HY, Park JW, Song HJ, Sohn HS, Kwon JW. The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea. PLoS One. 2017;12(1):e0169463. PMID: 28056068; doi: 10.1371/journal.pone.0169463.
Muhlack DC, Hoppe LK, Weberpals J, Brenner H, Schöttker B. The Association of Potentially Inappropriate Medication at Older Age With Cardiovascular Events and Overall Mortality: A Systematic Review and Meta-Analysis of Cohort Studies. J Am Med Dir Assoc. 2017;18(3):211-20. PMID: 28131719; doi: 10.1016/j.jamda.2016.11.025.
Cross AJ, George J, Woodward MC, et al. Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics. J Alzheimers Dis. 2017;60(2):349-58. PMID: 28869467; doi: 10.3233/JAD-170265.
Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64(5):492-8. PMID: 19067364; doi: 10.1002/ana.21509.
Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer’s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013;3(1). pii: e002080. PMID: 23299113; doi: 10.1136/bmjopen-2012-002080.
Mastroianni P de C, Polli LM, Trombotto V, Varallo FR. Risperidona ou Quetiapina em pacientes com diagnóstico provável de Doença de Alzheimer? Journal of Applied Pharmaceutical Sciences - JAPHAC; 2017;4(3):35-41. Available from: Available from: http://docs.wixstatic.com/ugd/e6f2ee_95020ebea79a4aea99365f3e8e605c48.pdf Accessed in 2020 (Feb 21).
Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476. PMID: 16437455; doi: 10.1002/14651858.CD003476.pub2.
Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease. Int J Geriatr Psychiatry. 2012;27(12):1248-57. PMID: 22374884; doi: 10.1002/gps.3769.
Mayer G, Jennum P, Riemann D, Dauvilliers Y. Insomnia in central neurologic diseases--occurrence and management. Sleep Med Rev. 2011;15(6):369-78. PMID: 21481621; doi: 10.1016/j.smrv.2011.01.005.
McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2016;11:CD009178. PMID: 27851868; doi: 10.1002/14651858.CD009178.pub3.
Lucchetta RC, da Mata BPM, Mastroianni PC. Association between Development of Dementia and Use of Benzodiazepines: A Systematic Review and Meta-Analysis. Pharmacotherapy. 2018; 38(10):1010-20. PMID: 30098211; doi: 10.1002/phar.2170.
Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I. Use of Benzodiazepines in Alzheimer’s Disease: A Systematic Review of Literature. Int J Neuropsychopharmacol. 2015;18(10):pyv055. PMID: 25991652; doi: 10.1093/ijnp/pyv055.
Pugazhenthi S. Metabolic Syndrome and the Cellular Phase of Alzheimer’s Disease. Prog Mol Biol Transl Sci. 2017;146:243-58. PMID: 28253987; doi: 10.1016/bs.pmbts.2016.12.016.
Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol. 2007;64(1):93-6. PMID: 17210814; doi: 10.1001/archneur.64.1.93.
Forgerini M, Mastroianni P de C. Monitoring compliance of Clinical Protocol and Therapeutic Guidelines for Alzheimer’s disease. Dement Neuropsychol. 2020;14(1):24-7. doi: 10.1590/1980-57642020dn14-010004
Mastroianni PC, Forgerini M. Compliance and drug-related problems in probable Alzheimer’s disease elderly. Int Psychogeriatr. 2019;1-2. PMID: 30722799; doi: 10.1017/S104161021800234X.
Mastroianni PC, Forgerini M. Drug administration adjustments for elderly patients with dysphagia: A case report. Dement Neuropsychol. 2018;12(1):97-100. PMID: 29682241; doi: 10.1590/1980-57642018dn12-010015.
Forgerini M, Lucchetta RC, Oliveira FM, et al. Impact of pharmacist intervention in patients with Alzheimer’s disease. Braz J Pharm Sci. 2020, in press.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
